Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Serdexmethylphenidate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,797Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ark Bio Gets China Approval For Aizhida In ADHD Treatment
    Ark Bio Gets China Approval For Aizhida In ADHD Treatment

    08 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ark-biopharmaceutical-receives-china-marketing-authorization-for-aizhida-for-the-treatment-of-adhd-302656307.html

    PR NEWSWIRE
    08 Jan 2026
    Share Share
    ArkBio's ADHD drug Azstarys Granted Priority Review by China NMPA
    ArkBio's ADHD drug Azstarys Granted Priority Review by China NMPA

    15 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/arkbios-new-drug-application-for-adhd-therapeutic-azstarys-accepted-and-granted-priority-review-by-china-nmpa-302481819.html

    PR NEWSWIRE
    15 Jun 2025
    Share Share
    Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
    Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

    28 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/28/2854508/16626/en/Zevra-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-Updates.html

    GLOBENEWSWIRE
    28 Mar 2024
    Share Share
    Journal Frontiers in Psychiatry Publishes Analysis of With ADHD
    Journal Frontiers in Psychiatry Publishes Analysis of With ADHD

    26 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/journal-frontiers-in-psychiatry-publishes-analysis-of-open-label-safety-study-showing-improvements-in-sleep-habits-for-children-with-adhd-after-treatment-with-azstarys-serdexmethylphenidate-and-dexmethylphenidate-301862645.html

    PR NEWSWIRE
    26 Jun 2023
    Share Share
    Corium's Medication AZSTARYS Had No Significant Impact on Children's Weight
    Corium's Medication AZSTARYS Had No Significant Impact on Children's Weight

    22 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/coriums-novel-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-had-no-clinically-significant-impact-on-childrens-weight-and-height-growth-rate-301830739.html

    PR NEWSWIRE
    22 May 2023
    Share Share
    Corium's Novel ADHD Medication AZSTARYS Shown Safe and Effective in Study
    Corium's Novel ADHD Medication AZSTARYS Shown Safe and Effective in Study

    22 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/coriums-novel-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-shown-safe-and-effective-in-long-term-study-301752562.html

    PR NEWSWIRE
    22 Feb 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.